Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

“Patients taking compounded tirzepatide injection are going to need to be transitioned to the FDA-approved drug Mounjaro or Zepbound,” Brunner said. “In many instances, it’s going to take ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

“Patients taking compounded tirzepatide injection are going to need to be transitioned to the FDA-approved drug Mounjaro or Zepbound,” Brunner said. “In many instances, it’s going to take some time.

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Eli Lilly, the manufacturer of Mounjaro and Zepbound, has clearly stated that any drugs sold online or elsewhere under the name “tirzepatide,” which contain only tirzepatide, are not FDA ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding ...

The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ...